Roche to Acquire Carmot Therapeutics in $2.7 Billion Deal

The Swiss pharmaceutical giant enters the weight-loss drug market, with potential to challenge current leaders Novo Nordisk and Eli Lilly.

Roche Holding AG is set to acquire Carmot Therapeutics Inc., a developer of weight-loss treatments, for an upfront payment of $2.7 billion, with potential for an additional $400 million if certain milestones are reached.
Carmot Therapeutics is currently researching three potential weight-loss treatments, with its lead asset, CT-388, being an injectable treatment for those with or without diabetes.
The acquisition could position Roche to compete with Novo Nordisk and Eli Lilly, current leaders in the weight-loss drug market.
Carmot's drugs are still in early stages of development, with a potential market launch in the 2030s.
The deal is expected to close in the first quarter of 2024.